Trovagene Inc. (NASDAQ:TROV)’s share price was down 3.5% during mid-day trading on Thursday . The company traded as low as $5.39 and last traded at $5.49, with a volume of 401,748 shares traded. The stock had previously closed at $5.69.

TROV has been the subject of several research reports. Argus downgraded Trovagene from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. Cantor Fitzgerald downgraded Trovagene from a “buy” rating to a “hold” rating and dropped their price target for the stock from $9.00 to $5.00 in a research note on Monday, April 25th. Leerink Swann downgraded Trovagene from an “outperform” rating to a “market perform” rating in a research note on Monday, April 25th. Zacks Investment Research upgraded Trovagene from a “sell” rating to a “hold” rating in a research note on Wednesday, July 13th. Finally, Piper Jaffray Cos. restated a “hold” rating and issued a $5.00 price target (down from $8.00) on shares of Trovagene in a research note on Thursday, May 12th. Seven analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $6.96.

The firm’s market cap is $168.12 million. The firm has a 50 day moving average price of $4.80 and a 200-day moving average price of $4.79.

Trovagene (NASDAQ:TROV) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.07. Equities research analysts expect that Trovagene Inc. will post ($1.26) EPS for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.